Ernexa Therapeutics Inc (NASDAQ:ERNA) shares are skyrocketing Tuesday. The market is seemingly reacting to the company's latest investor segment featuring Chief Scientific Officer Dr. Robert Pierce, along with fresh attention on the potential of ERNA‑101 in ovarian cancer. Here’s what you should know.

The company released a new Virtual Investor KOL Connect segment where Dr. Pierce discusses the challenges of ovarian cancer and the shortcomings of current treatment options. The conversation focuses on the patient journey, the limited durability of existing therapies and the need for more effective approaches.

ERNA‑101 And The Evolving Treatment Landscape

In the segment, Dr. Pierce explains how Ernexa is approaching ovarian cancer differently at the biological level. He outlines how ERNA‑101 may improve outcomes and enhance the patient experience compared to current standards of care. The discussion positions ERNA‑101 as a potential answer to long‑standing gaps in ovarian cancer treatment, potentially helping drive renewed interest in the stock.

Additional Momentum From Upcoming Investor Events

Ernexa also announced that President and CEO Sanjeev Luther and Dr. Pierce will participate in a Virtual Investor Closing Bell event on May 13. During the event, they will review the company's recently announced preclinical ovarian cancer data for ERNA‑101. Those results showed complete tumor elimination and 100% survival in ovarian cancer models when ERNA‑101 was combined with PD‑1 blockade.

They will also discuss how ERNA‑101 may help convert immunologically cold tumors into environments that support stronger immune responses.

The Tape Says "Breakout," The Trend Says "Not So Fast"

Technically, the rally is doing what sharp rallies do: it's forcing the stock well above its nearer-term reference points. Ernexa is trading 119.7% above the 20-day SMA of $5.11 and 93.5% above the 50-day SMA of $5.80, a sign that the move isn't just a gentle drift, it's a momentum event. But the longer-term damage is still very much on the chart. The stock remains 23% below the 100-day SMA ($14.59) and 55% below the 200-day SMA of $24.97, consistent with a 12-month drop of 85.82%. In other words: today's buyers are fighting the recent past, not confirming it.

Momentum traders will point to MACD as the cleaner tell right now: it's above its signal line and the histogram is positive, which suggests upside pressure is improving versus the prior downswing. That's constructive, but it's also the kind of "early improvement" signal that can either mark the start of a base, or just the middle chapter of a volatility loop.

Key levels are straightforward and, in a move like this, potentially unforgiving:

  • Key Support: $5.80 — aligns with the 50-day SMA, a common area where pullbacks try to stabilize
  • Key Resistance: $7.49 — sitting right on the 50-day EMA, a level that often acts as a "make-or-break" pivot after sharp moves

ERNA Shares Are Soaring

ERNA Price Action: Ernexa shares were up 47.99% at $10.67 at the time of publication on Tuesday, according to Benzinga Pro.

Read Also: Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data

Image: Billion Photos/Shutterstock.com